These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 4060364)

  • 61. Preliminary evaluation of urinary polyamines in the diagnosis of genitourinary tract malignancy.
    Sanford EJ; Drago JR; Rohner TJ; Kessler GF; Sheehan L; Lipton A
    J Urol; 1975 Feb; 113(2):218-21. PubMed ID: 1113419
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genitourinary cancer.
    Ozols RF; Yagoda A
    Cancer Chemother Biol Response Modif; 1987; 9():280-302. PubMed ID: 2856337
    [No Abstract]   [Full Text] [Related]  

  • 63. Genitourinary cancer.
    Hudes GR; Grana G; Deshields MS; Ozols RF
    Cancer Chemother Biol Response Modif; 1992; 13():508-40. PubMed ID: 1389919
    [No Abstract]   [Full Text] [Related]  

  • 64. [Molecular and immunological approach to hematological disease: detection and analysis of intracellular modified nucleosides by flow cytometry].
    Hoshino A; Honda I; Ishimori A; Itoh K; Mizugaki M; Nose M
    Rinsho Byori; 1990 Jul; 38(7):756-64. PubMed ID: 2402080
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preparation of a monoclonal antibody specific for 1-methyladenosine and its application for the detection of elevated levels of 1-methyladenosine in urines from cancer patients.
    Itoh K; Mizugaki M; Ishida N
    Jpn J Cancer Res; 1988 Oct; 79(10):1130-8. PubMed ID: 3143701
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genitourinary cancer.
    Ozols RF; Yagoda A
    Cancer Chemother Biol Response Modif; 1990; 11():602-29. PubMed ID: 2171615
    [No Abstract]   [Full Text] [Related]  

  • 67. Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers.
    Struck W; Siluk D; Yumba-Mpanga A; Markuszewski M; Kaliszan R; Markuszewski MJ
    J Chromatogr A; 2013 Mar; 1283():122-31. PubMed ID: 23465127
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chromatographic, capillary electrophoretic and matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of urinary modified nucleosides as tumor markers.
    Liebich HM; Müller-Hagedorn S; Klaus F; Meziane K; Kim KR; Frickenschmidt A; Kammerer B
    J Chromatogr A; 2005 Apr; 1071(1-2):271-5. PubMed ID: 15865203
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reversed-phase high-performance liquid chromatographic investigation of urinary normal and modified nucleosides of cancer patients.
    Xu G; Di Stefano C; Liebich HM; Zhang Y; Lu P
    J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(2):307-13. PubMed ID: 10517352
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modified Nucleosides - Molecular Markers Suitable for Small-volume Cancer?
    Opitz P; Herbarth O; Seidel A; Boehm A; Fischer M; Mozet C; Dietz A; Wichmann G
    Anticancer Res; 2018 Nov; 38(11):6113-6119. PubMed ID: 30396926
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control.
    Seidel A; Brunner S; Seidel P; Fritz GI; Herbarth O
    Br J Cancer; 2006 Jun; 94(11):1726-33. PubMed ID: 16685264
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Urinary excretion of modified purines and nucleosides in immunodeficient children.
    Mills GC; Schmalstieg FC; Goldblum RM
    Biochem Med; 1985 Aug; 34(1):37-51. PubMed ID: 4052062
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Analysis of urinary nucleosides. IV. Identification of urinary purine nucleosides by liquid chromatography/electrospray mass spectrometry.
    Dudley E; Lemière F; Van Dongen W; Tuytten R; El-Sharkawi S; Brenton AG; Esmans EL; Newton RP
    Rapid Commun Mass Spectrom; 2004; 18(22):2730-8. PubMed ID: 15499664
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reversed-phase liquid chromatographic investigation of nucleosides and bases in mucosa and modified nucleosides in urines from patients with gastrointestinal cancer.
    Nakano K; Shindo K; Yasaka T; Yamamoto H
    J Chromatogr; 1985 Sep; 332():127-37. PubMed ID: 4055938
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correlations of pseudouridine in 8-hour and 24-hour urinary samples determined by high-performance liquid chromatography.
    Sjølin KE
    Urol Res; 1982; 10(5):245-8. PubMed ID: 7164220
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
    Bigot F; Bonnet C; Massard C
    Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Cholesterol and urinary tract diseases].
    Frick J; Spiteller G
    Z Urol Nephrol; 1968 Dec; 61(12):833-8. PubMed ID: 4183283
    [No Abstract]   [Full Text] [Related]  

  • 78. [Urinary excretion of cholesterol in various diseases. (Especially in cancer of the urogenital system)].
    Spiteller-Friedmann M; Spiteller G; Spiteller H; Frick J
    Osterr Z Erforsch Bekampf Krebskr; 1971; 26(1):25-35. PubMed ID: 5171242
    [No Abstract]   [Full Text] [Related]  

  • 79. Genitourinary cancer.
    Hudes GR; Ozols RF; Schilder RJ
    Cancer Chemother Biol Response Modif; 1991; 12():509-48. PubMed ID: 1718377
    [No Abstract]   [Full Text] [Related]  

  • 80. Carcinoma of urinary tract. Clinical significance of urinary phosphokinase activity in diagnosis.
    Block NL; Jaksy J; Tessler AN
    Urology; 1974 Aug; 4(2):174-81. PubMed ID: 4850881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.